StockNews.AI
SCNI
StockNews.AI
21 days

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

1. SCNI's PC111 shows potential in treating pemphigus and SJS/TEN. 2. Peer-reviewed publication confirms PC111’s safety and efficacy in multiple models. 3. PC111 targets final disease steps, offering a fast-acting and safer profile. 4. The annual market opportunity for PC111 exceeds one billion dollars. 5. Acquisition of Pincell may accelerate PC111 development into clinical studies.

11m saved
Insight
Article

FAQ

Why Bullish?

The confirmation of PC111’s efficacy strengthens its market position. Positive peer-reviewed validation typically leads to investor confidence and potential price appreciation, as seen with companies like Regeneron during successful trial announcements.

How important is it?

The article discusses breakthrough findings that could significantly enhance SCNI’s commercial prospects and investor interest. With a clear path to regulatory approvals and market entry, this information is highly relevant to SCNI’s stock performance.

Why Long Term?

Successful advancement to clinical studies could take several years but has significant market potential. The projected market entry within 3-4 years indicates a long-term horizon for impact.

Related Companies

REGNRITX
New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models , /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) biological products and providing boutique CDMO services, announced the publication of a new peer-reviewed article in the Journal of Dermatological Treatment validating the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. Authored by Dr. Roberta Lotti and colleagues from the University of Modena and Pincell Srl, the paper expands on Dr. Lotti's prior award-winning research that earned the "Oscar of Italian Dermatology" and was highlighted in Scinai's June 26 press release. The new publication "Treatment of pemphigus and other neglected skin conditions with PC111 a human anti-Fas Ligand monoclonal antibody: a potential disease modifier" confirms PC111's ability to prevent blister formation in in vitro, ex vivo, and in vivo humanized models of pemphigus by targeting soluble Fas Ligand (sFasL), a key effector of keratinocyte apoptosis and acantholysis. Scientific and Translational Advancement Building upon prior ex vivo studies, the research introduces new data from a proprietary humanized FasL mouse model, in which PC111 significantly reduced disease activity. Collectively, the data confirms PC111's unique, non-immunosuppressive mode of action: acting locally at the keratinocyte level and downstream of the immune system. In addition to pemphigus, the authors highlight PC111's promise in SJS/TEN, a life-threatening dermatological emergency. Preclinical models show PC111 prevents FasL-mediated keratinocyte apoptosis and ocular damage, indicating potential for early intervention in this high-mortality condition. Unmet Need and Market Potential Current treatments for pemphigus and SJS/TEN rely on chronic, systemic immunosuppression. In pemphigus, this typically includes steroids and Rituximab, which are slow-acting and associated with serious side effects. Other approaches—including BTK and FcRn inhibitors—have failed in late-stage development. By targeting the final step in disease pathology rather than suppressing the immune system, PC111 offers a differentiated, fast-acting, and safer therapeutic profile. Combined, the two indications represent an annual market opportunity exceeding one billion dollars. Development Path and Strategic Outlook Subject to Scinai's exercise of its option to acquire Pincell, the two companies plan to advance PC111 through IND-enabling studies and into clinical development. PC111 has already been granted orphan drug designation in the EU, and a similar status will be pursued also in the U.S. The two companies are exploring accelerated approval pathways that could allow market entry within approximately three to four years. Risk-Mitigating Program Structure Scinai and Pincell have embedded several strategic advantages into the PC111 program: Expert Leadership: The PC111 program is led by its inventor, Prof. Carlo Pincelli (CMO, Pincell), together with Dr. Antonino Amato (CEO, Pincell), Dr. Roberta Lotti (Senior Researcher and Project Manager), and Dr. Brydon Bennett (CSO, Pincell). They are supported by Scinai's Scientific Advisory Board, which includes Prof. Michael Schön and Dr. Jonathan Sadeh, both recognized leaders in dermatology and immunotherapy. Robust Evidence: PC111's efficacy is supported by multiple peer-reviewed publications, most notably the award-winning 2023 Frontiers in Immunology article and a new 2025 publication in the Journal of Dermatological Treatment. Non-Dilutive Funding: Pending a final decision expected in the third quarter of 2025, Scinai may receive up to 80% cost coverage through a €15 million FENG grant to support development through IND readiness. Regulatory Strategy: The combination of orphan designation, high unmet medical need, and a well-defined mechanism of action supports a realistic path toward Breakthrough Therapy designation and/or Accelerated Approval. CEO Statement "This new publication further validates our conviction that PC111 has the potential to transform the treatment landscape for pemphigus and SJS/TEN," said Amir Reichman, CEO of Scinai. "The scientific leadership and development expertise of the Pincell's team have been instrumental, and with their expected integration into Scinai upon exercise of the option, we are well positioned to advance PC111. With strong science, regulatory clarity, and substantial market potential, we believe PC111 can deliver life-changing benefits to patients, and meaningful value to shareholders." About Scinai Immunotherapeutics Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products, starting with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs; and the other, a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early-stage biotech drug development projects. Company website: www.scinai.com Company Contacts Investor Relations - Allele Capital Partners | +1 978 857 5075 | [email protected]    Business Development | +972 8 930 2529 | [email protected] Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to  the risk that Scinai will be unable to exercise its option to acquire Pincell; that Scinai may be required to resell its shares in Pincell to the previous shareholders under certain conditions; a delay in the market entry of Pincell; the risk that the annual addressable market of PC111 will be lower than anticipated; the risk that Scinai may be unable to remain compliant with the continued listing requirements of Nasdaq; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including for PC111 or the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in-licensing other nanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of nanoAbs or PC111 will not be met or that Scinai will not be successful in bringing the nanoAbs or PC111 towards commercialization; the risk of a delay in the preclinical and clinical trials data for nanoAbs or PC111, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 7, 2025, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason. Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg SOURCE Scinai Immunotherapeutics Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News